Ann: Kazia paxalisib Phase II interim data, page-23

Good that he was asked about future funding requirements.
The current CR is not sufficient to take us through to the end of GBM Agile, but then he is not selling the whole house to make that happen.
The possibility of partnership before then was specifically mentioned, as are of course other options.
Maximising value to shareholders while getting product to market as quickly as possible are key drivers.
- of course that applies to shareholders at the time any deal is done, not necessarily so much to current shareholders..........